New and Future Resuscitation Fluids for Trauma Patients Using Hemoglobin and Hypertonic Saline

Anesthesiology Clinics

Volumn 31, Issue 1, 2013, Pages 1-19

  Galvagno, Samuel M ^a   Mackenzie, Colin F ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulopathy of trauma; Frozen blood; Frozen plasma and platelets; Hemoglobin based oxygen carriers (HBOC); Hypertonic saline solutions (HSS); Inflammatory response; Resuscitation; Trauma

Indexed keywords

AFTERSHOCK (DRUG); DIASPIRIN CROSSLINKED HEMOGLOBIN; FRESH FROZEN PLASMA; HEM 0114; HEM 0115; HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; MALPEGYLATED HEMOGLOBIN; POLYMERIZED HEMOGLOBIN; RINGER LACTATE SOLUTION; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BILIRUBIN BLOOD LEVEL; BIOLOGICAL MONITORING; BLEEDING; BLOATING; BLOOD COMPONENT THERAPY; CRYOPRESERVATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SAFETY; FLUID RESUSCITATION; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC SHOCK; HUMAN; JAUNDICE; LACTIC ACIDOSIS; NAUSEA AND VOMITING; RASH; REVIEW; SIDE EFFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE PERFUSION; UNSPECIFIED SIDE EFFECT;

EID: 84872792067     PISSN: 19322275     EISSN: 22103538     Source Type: Journal    
DOI: 10.1016/j.anclin.2012.10.004     Document Type: Review

References (106)

1. Bellamy R. The causes of death in conventional land warfare. Mil Med 1984, 149:55-62.
2. Dutton D., Stansbury L., Leone S., et al. Trauma mortality in mature trauma systems: are we doing better? An analysis of trauma mortality patterns, 1997-2008. J Trauma 2010, 69(3):620-626.
3. Borgman M., Spinella P., Perkins J., et al. The ratio of blood products transfused affects mortality in patients receiving massive blood transfusions at a combat support hospital. J Trauma 2007, 63(4):805-813.
4. Clarke J., Trooskin S., Doshi P., et al. Time to laparotomy for intra-abdominal bleeding from trauma does affect survival for delays up to 90 minutes. J Trauma 2002, 52(3):420-425.
5. de Biasi A.R., Stansbury L.G., Dutton R.P., et al. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma. Transfusion 2011, 51(9):1925-1932.
6. Spinella P., Perkins J., Grathwohl K., et al. Effect of plasma and red blood cell transfusion on survival in patients with combat related traumatic injuries. J Trauma 2008, 64(Suppl 2):S69-S77.
7. Ketchum L., Hess J., Hippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma 2006, 60(Suppl 6):S51-S58.
8. Gonzalez E., Moore F., Holcomb J., et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007, 62(1):112-119.
9. Cinat M., Wallace W., Nastanski F., et al. Improved survival following massive blood transfusion in patients who have undergone trauma. Arch Surg 1999, 134(9):964-968.
10. Perkins J., Schreiber M., Wade C., et al. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma 2007, 62(5):1095-1099.
11. White J., Stannard A., Burkhardt G., et al. The epidemiology of vascular injury in the wars in Iraq and Afghanistan. Ann Surg 2011, 253(6):1184-1189.
12. Starnes B., Beekley A., Sebesta J., et al. Extremity vascular injuries on the battlefield: tips for surgeons deploying to war. J Trauma 2006, 60(2):432-442.
13. Woodward E., Clouse W., Eliason J., et al. Penetrating femoropopliteal injury during modern warfare: experience of the Balad Vascular Registry. J Vasc Surg 2008, 47(6):1259-1264.
14. Claridge J., Sawyer R., Schulman A., et al. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg 2002, 68(7):566-572.
15. Sauaia A., Moore F., Moore E., et al. Early predictors of postinjury multiple organ failure. Arch Surg 1994, 129(1):39-45.
16. Moore F., Moore E., Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg 1997, 132(6):620-624.
17. Malone D., Dunne J., Putnam J.T.A., et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 2003, 54(5):898-905.
18. Como J., Dutton R., Scalea T., et al. Blood transfusion rates in the care of acute trauma. Transfusion 2004, 44(6):809-813.
19. Moore E., Cheng A., Moore H., et al. Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the US multicenter prehospital trial. World J Surg 2006, 30(7):1247-1257.
20. Reid T. Hb-based oxygen carriers: are we there yet?. Transfusion 2003, 43(2):280-287.
21. Mackenzie C., Moon-Massat P., Shander A., et al. When blood is not an option: factors affecting survival after use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg 2010, 110(3):685-693.
22. Branas C., MacKenzie E., Williams J., et al. Access to trauma centers in the United States. JAMA 2005, 293(1):2626-2633.
23. Gould S., Moore E., Hoyt D., et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 2002, 195(4):445-452.
24. Heckbert S., Vedder N., Hoffman W., et al. Outcome after hemorrhagic shock in trauma patients. J Trauma 1998, 45(3):545-549.
25. Sloan E., Koenigsberg M., Gens D., et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock. A randomized controlled efficacy trial. JAMA 1999, 282(19):1857-1864.
26. Mattox K., Maningas P., Moore E., et al. Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension: the U.S.A. multicenter trial. Ann Surg 1991, 213(5):482-491.
27. Bickell W., Wall M., Pepe P., et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994, 331(17):1105-1109.
28. Landro L. The informed patient: a dangerous gap in trauma care; systems to transfer patients to best-equipped hospitals fall short in most states. Wall Street Journal October 3, 2007.
29. Silliman C., Moore E., Johnson J., et al. Transfusion of the injured patient: proceed with caution. Shock 2004, 21(4):291-299.
30. Stowell C., Levin J., Spiess B., et al. Progress in the development of RBC substitutes. Transfusion 2001, 41(2):287-299.
31. Rudolph A., Cliff R., Spargo B., et al. Transient changes in the mononuclear phagocytes system following administration of blood substitutes, liposome-encapsulated hemoglobin. Biomaterials 1994, 15(10):796-804.
32. Klein H., Spahn D., Carson J. Red blood cell transfusion in clinical practice. Lancet 2007, 370(9585):415-426.
33. Leong B., Reynolds P., Tiba M., et al. Effects of a combination hemoglobin based oxygen carrier-hypertonic saline solution on oxygen transport in the treatment of hemorrhagic shock. Resuscitation 2011, 82:937-943.
34. Vandergriff K., Young M., Keipert P., et al. The safety profile of Hemospan: a new oxygen therapeutic designed using maleimide poly(ethylene) glycol conjugation to human hemoglobin. Transfus Altern Transfus Med 2008, 9:213-225.
35. Zou S., Musavi F., Notari E., et al. Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006. Transfusion 2008, 48(12):2531-2539.
36. Vamvakas E., Taswell H. Epidemiology of blood transfusion. Transfusion 1994, 34(6):464-470.
37. Jahr J., Mackenzie C., Pearce L., et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008, 64(6):1484-1497.
38. Gawryl M., Moon-Massat P., Pearce L. Chapter 37. Blood substitutes 2006, 437-450. Academic Press, London. R. Winslow (Ed.).
39. US Food and Drug Administration. Code of Federal Regulations Title 21, parts 312 and 316. Expanded access to investigational drugs for treatment use. 74FR40900. 2009.
40. Silverman T., Weiskopf R. Hemoglobin-based oxygen carriers current status and future directions. Anesthesiology 2009, 111(5):946-963.
41. Freilich D., Pearce L., Pitman A., et al. HBOC-201 vasoactivity in a phase III clinical trial in orthopedic surgery subjects-extrapolation of potential risk for acute trauma trials. J Trauma 2009, 66(2):365-376.
42. Levien L. South Africa: clinical experience with hemopure. ISBT Sci Ser 2006, 1:167-173.
43. Winslow R. Red cell substitutes. Semin Hematol 2007, 44:51-59.
44. Olofsson C., Ahl T., Johansson T., et al. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology 2006, 105(6):1153-1163.
45. Olofsson O., Nygards E., Ponzer S., et al. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med 2008, 18(1):28-39.
46. van der Linden P., Gazdizik T.S., Jahoda D., et al. A double-blind, randomized, multicenter study of MP4OX for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. Anesth Analg 2011, 112(4):759-773.
47. Olofsson C., Gorecki A., Dirksen R., et al. Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study. Anesthesiology 2011, 114(5):1048-1063.
48. Beuzard Y., Lubin B., Rosa J. Sickle cell disease and thalassemia: new trends in therapy 1995, vol. 234. Colloque INSERM/John Libbey Eurotext, Montrogue (France).
49. Dietz N., Joyner M., Warner M. Blood substitutes: fluids, drugs, or miracle solutions?. Anesth Analg 1996, 82(2):390-405.
50. Alayash A. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents or oxidants?. Nat Biotechnol 1999, 17:545-549.
51. Natanson S., Kern S., Lurie P., et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008, 299(12):2304-2312.
52. Levien L., Hodgson R., James M. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008, 300:1295. [letter].
53. Keipert P., Olofsson C., Winslow R. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008, 300:1295-1296. [letter].
54. Shander A., Javidroozi M., Thompson G. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008, 300:1296-1297. [letter].
55. Sauaia A., Moore E., Banerjee A. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008, 300:1297. [letter].
56. Hekkert M.T.L., Dube G., Regar E., et al. Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs. Am J Physiol Heart Circ Physiol 2010, 298(3):H1103-H1113.
57. Meliga E., Vranckx P., Regar E., et al. Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic results. EuroIntervention 2008, 4(1):99-107.
58. Fitzgerald M., Chan J., Ross A. A synthetic haemoglobin-based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anemia following trauma. Med J Aust 2011, 194:471-473.
59. Mackenzie C. Hemoglobin-based oxygen carriers: is the benefit worth the risk?. Br J Hosp Med (Lond) 2009, 70(1):26-30.
60. Lelkens C.C.M., Koning J.G., de Kort I.B.G., et al. Experiences with frozen blood products in the Netherlands military. Transfus Apher Sci 2006, 34(3):289-298.
61. Velasco I.T., Pontieri V., Rocha e Silva M., et al. Hyperosmotic NaCl and severe hemorrhagic shock. Am J Physiol 1980, 239:H664-H673.
62. Kramer G. Hypertonic resuscitation: physiological mechanisms and recommendations for trauma care. J Trauma 2003, 54:S89-S99.
63. Patanwala A., Amini A., Erstad B. Use of hypertonic saline injection in trauma. Am J Health Syst Pharm 2010, 67:1920-1928.
64. Dubick M., Bruttig S., Wade C. Issues of concern regarding the use of hypertonic/hyperoncotic fluid resuscitation of hemorrhagic hypotension. Shock 2006, 25(4):321-328.
65. Ropper A. Hyperosmolar therapy for raised intracranial pressure. N Engl J Med 2012, 367:746-752.
66. Bratton S., Chestnut R., Ghajar J., et al. II. Hyperosmolar therapy. J Neurotrauma 2007, 24(Suppl 1):S14-S20.
67. Rockswold G., Solid C., Paredes-Andrade E., et al. Hypertonic saline and its effect on intracranial pressure, cerebral perfusion pressure, and brain tissue oxygen. Neurosurgery 2009, 65:1035-1042.
68. Pinto F., Capone-Neto A., Prist R., et al. Volume replacement with lactated Ringer's or 3% hypertonic saline solution during combined experimental hemorrhagic shock and traumatic brain injury. J Trauma 2006, 60:758-764.
69. Belba M., Petrela E., Belba G. Comparison of hypertonic vs isotonic fluids during resuscitation of severely burned patients. Am J Emerg Med 2009, 27:1091-1096.
70. Standvik G. Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure. Anaesthesia 2009, 64:990-1003.
71. Oliveira R., Velasco I., Soriano F.G. Clinical review: hypertonic saline resuscitation in sepsis. Crit Care 2002, 6:418-423.
72. Banks C., Furyk J. Review article: hypertonic saline use in the emergency department. Emerg Med Australas 2008, 20:294-305.
73. Galvagno S. Emergency pathophysiology 2004, Teton NewMedia, Jackson (WY).
74. Tyagi R., Donaldson K., Loftus C., et al. Hypertonic saline: a clinical review. Neurosurg Rev 2007, 30:277-290.
75. Kolsen-Petersen J. Immune effect of hypertonic saline: fact or fiction?. Acta Anaesthesiol Scand 2004, 48:667-678.
76. Deitch E., Shi H., Feketeova E., et al. Hypertonic saline resuscitation limits neutrophil activation after trauma-hemorrhagic shock. Shock 2003, 19(4):328-333.
77. Hashiguchi N., Lum L., Romeril E., et al. Hypertonic saline resuscitation: efficacy may require early treatment in severely injured patients. J Trauma 2007, 62:299-306.
78. Pascual J., Khwaja K., Chaudhury P., et al. Hypertonic saline and the microcirculation. J Trauma 2003, 54:S133-S140.
79. Hirsh M., Dyugovskaya L., Bashenko Y., et al. Reduced rate of bacterial translocation and improved variables of natural killer cell and T-cell activity in rats surviving controlled hemorrhagic shock and treated with hypertonic saline. Crit Care Med 2002, 30:861-867.
80. Homma H., Deitch E., Feketeova E., et al. Small volume resuscitation with hypertonic saline is more effective in ameliorating trauma-hemorrhagic shock-induced lung injury, neutrophil activation and red blood cell dysfunction than pancreatic protease inhibition. J Trauma 2005, 59:266-272.
81. Deree J., de Campos T., Shenvi E., et al. Hypertonic saline and pentoxyfylline attenuates gut injury and hemorrhagic shock: the kinder, gentler resuscitation. J Trauma 2007, 62:818-828.
82. Chen L., Su M., Chen P., et al. Hypertonic saline enhances host defense and reduces apopotosis in burn mice by increasing toll-like receptors. Shock 2011, 35(1):59-66.
83. Yoon Y., Choi S., Hong Y., et al. Effect of hypertonic saline and macrophage migration inhibitory factor in restoration of T cell dysfunction. J Korean Surg Soc 2011, 81(4):229-234.
84. Shi H., Deitch E., Xu D., et al. Hypertonic saline improves intestinal mucosa barrier function and lung injury after trauma-hemorrhagic shock. Shock 2002, 17(6):496-501.
85. Vincenzi R., Cepeda L., Pirani W., et al. Small volume resuscitation with 3% hypertonic saline decrease inflammatory response and attenuates end organ damage after controlled hemorrhagic shock. Am J Surg 2009, 198:407-414.
86. Bunn F., Roberts I., Tasker R., et al. Hyeprtonic versus near isotonic crystalloid for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2007, (3). (Assessed as up to date, October 15, 2007), CD002045.
87. Rotstein O. Novel strategies for immunomodulation after trauma: revisiting hypertonic saline as a resuscitation strategy for hemorrhagic shock. J Trauma 2000, 49:580-583.
88. Younes R., Aun F., Ching C., et al. Prognostic factors to predict outcome following the administration of hypertonic/hyperoncotic solution in hypovolemic patients. Shock 1997, 7(2):79-83.
89. Wade C., Grady J., Kramer G. Efficacy of hypertonic saline dextran fluid resuscitation for patients with hypotension from penetrating trauma. J Trauma 2003, 54(Suppl 5):S144-S148.
90. DuBose J., Kobayashi L., Lozaornio A., et al. Clinical experience using 5% hypertonic saline as a safe alternative fluid for trauma. J Trauma 2010, 68:1172-1177.
91. Charalambous M., Swoboda S., Lipsett P. Perioperative hypertonic saline may reduce postoperative infections and lower mortality rates. Surg Infect (Larchmt) 2008, 9:67-74.
92. Bulger E., Jurkovich G., Nathens A., et al. Hypertonic resuscitation of hypovolemic shock after blunt trauma. Arch Surg 2008, 143(2):139-148.
93. Perner A., Haase N., Guttormsen A., et al. Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, 367(2):124-134.
94. Lissauer M., Chi A., Kramer M., et al. Association of 6% hetastarch resuscitation with adverse outcomes in critically ill trauma patients. Am J Surg 2011, 202(1):53-58.
95. Coimbra R. 3% and 5% hypertonic saline. J Trauma 2011, 70(5):S25-S26.
96. Marko N. Hyperosmolar therapy for intracranial hypertension: time to dispel antiquated myths. Am J Respir Crit Care Med 2012, 185(5):467-478.
97. Schimetta W., Schochl H., Kroll W., et al. Safety of hypertonic hyperoncotic solutions-a survey from Austria. Wien Klin Wochenschr 2002, 114(3):89-95.
98. Moran M., Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 1987, 317:150-153.
99. Chertow G., Mason P., Vaage-Nilsen O., et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004, 19(6):1571-1575.
100. Department of Health and Human Services Topic III: Prophylaxis of dextran-induced anaphylactoid reactions (DIAR) by dextran 1 pre-administration 2005, Food and Drug Administration, Blood Products Advisory Committee, Gaithersburg (MD).
101. Hedin H., Richter W., Ring J. Dextran-induced anaphylactoid reactions in man: role of dextran reactive antibodies. Int Arch Allergy Appl Immunol 1976, 52(1-4):145-159.
102. Ljungstrom K., Renck H., Hedin H., et al. Prevention of dextran-induced anaphylactic reactions by hapten inhibition. I. A Scandinavian multicenter study on the effects of 10 mL dextran 1, 15% administered before dextran 70 or dextran 40. Acta Chir Scand 1983, 149(4):341-348.
103. Agudelo J., Flierl M., Smith W., et al. Influence of preoperative 7.5% hypertonic saline on neutrophil activation after reamed intramedullary nailing of femur shaft fractures: a prospective randomized pilot study. J Orthop Trauma 2012, 26:86-91.
104. Zakaria E., Tsakadze N., Garrison R. Hypertonic saline resuscitation improves intestinal microcirculation in a rat model of hemorrhagic shock. Surgery 2006, 140:579-588.
105. Deree J., Martins J., Leedom A., et al. Hypertonic saline and pentoxifylline reduces hemorrhagic shock resuscitation-induced pulmonary inflammation through attenuation of neutrophil degranulation and proinflammatory mediator synthesis. J Trauma 2007, 62:104-111.
106. Rizoli S., Rhind S., Shek P., et al. The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock. Ann Surg 2006, 243:47-57.